Literature DB >> 3124681

Optimal timing of colonoscopy to screen for cancer in ulcerative colitis.

B A Lashner1, S B Hanauer, M D Silverstein.   

Abstract

Patients with ulcerative colitis have a high risk of colon cancer that increases with duration of disease. Annual colonoscopy with biopsies for 99 patients with pancolitis and a mean duration of disease at entry of 17 years was evaluated. The outcomes of mucosal dysplasia or cancer were analyzed to determine the annual risk (hazard rate) of high-grade dysplasia or colon cancer. The hazard rates were used to recommend screening intervals. The delay in the diagnosis of cancer is minimized for any given number of tests when the time between tests is inversely proportional to the square root of the hazard rate. Since the hazard rate for cancer increases with duration of disease, intervals for screening tests should not be uniform. For a range of reasonable marginal benefits from additional testing, the number of tests recommended is less than the number of tests done in fixed-interval screening programs. Scheduling screening tests using patient-specific hazard rates to minimize the delay in the diagnosis of cancer reduces the number of colonoscopies, associated cost, and morbidity.

Entities:  

Mesh:

Year:  1988        PMID: 3124681     DOI: 10.7326/0003-4819-108-2-274

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  13 in total

1.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

Authors:  J A Eaden; J F Mayberry
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 2.  Colonoscopic surveillance in ulcerative colitis--dysplasia through the looking glass.

Authors:  J B Fozard; M F Dixon
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

3.  Colonoscopy, mucosal biopsy and brush cytology in the assessment of patients with colorectal inflammatory bowel disease.

Authors:  W H Isbister; R K Gupta
Journal:  Surg Endosc       Date:  1989       Impact factor: 4.584

4.  Inflammatory bowel disease stimulates formation of carcinogenic N-nitroso compounds.

Authors:  T M C M de Kok; L G J B Engels; E J Moonen; J C S Kleinjans
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 5.  Screening for gastrointestinal cancer: an epidemiological review.

Authors:  J Weil; M J Langman
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

Review 6.  Biology of colorectal cancer in ulcerative colitis.

Authors:  B A Lashner; B D Shapiro
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

7.  A decision analysis of surveillance for colorectal cancer in ulcerative colitis.

Authors:  F Delcò; A Sonnenberg
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

8.  Risk of Malignant Cancers in Inflammatory Bowel Disease.

Authors:  Simone Y Loo; Maria Vutcovici; Alain Bitton; Peter L Lakatos; Laurent Azoulay; Samy Suissa; Paul Brassard
Journal:  J Crohns Colitis       Date:  2019-09-27       Impact factor: 9.071

9.  Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.

Authors:  Joel H Rubenstein; Akbar K Waljee; Joanne M Jeter; Fernando S Velayos; Uri Ladabaum; Peter D R Higgins
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

10.  Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis.

Authors:  B A Lashner
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.